SCHEMBL25891793

SCHEMBL25891793

NC(=O)c1c(-c2ccc(N)cc2)n[nH]c1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.43
GFER P55789 1/20 0.43
FGFR1 P11362 1/20 0.42
FGFR2 P21802 1/20 0.42
ALPL P05186 1/20 0.41
MAP2K4 P45985 4/20 0.39
MAPK1 P28482 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
MAPKAPK3 Q16644 1/20 0.39
MAPK6 Q16659 1/20 0.39
MAPKAPK5 Q8IW41 1/20 0.39
KDR P35968 4/20 0.39
PDE5A O76074 1/20 0.38
PDE1A P54750 1/20 0.38
PDE1B Q01064 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE1C Q14123 1/20 0.38
PDE3A Q14432 1/20 0.38
PDGFRB P09619 2/20 0.36
PARP1 P09874 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8308326 0.87 SIRT1 (0.45) GAAGFERALPLMAP2K4
SCHEMBL25891692 0.86 GAA (0.47) GAAGFERALPLMAP2K4KDR
SCHEMBL16197120 0.81 SCN9A (0.50) BTKPARP10
SCHEMBL24518223 0.81 PLA2G2A (0.47) GAAMAP2K4BTKMEN1KMT2A
SCHEMBL18700175 0.79 LTA4H (0.48) GAAGFERBTKMEN1KMT2A
SCHEMBL25892423 0.79 ALDH1A1 (0.44) GAAGFERALPLMAP2K4MAPK1
SCHEMBL25892400 0.76 PLK4 (0.50) GAAGFERMAPK1KDRPDE5A
SCHEMBL17637853 0.76 MAP2K4 (0.47) GAAGFERMAP2K4MAPK1MAPKAPK2
SCHEMBL18700210 0.75 CHEK2 (0.48) GAAGFERMAP2K4MAPK1MAPKAPK2
SCHEMBL18700136 0.74 BTK (0.47) BTKALDH1A1PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227429-A1 SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP1 GAA 2055/4885GFER 1775/4885FGFR1 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.